A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis

Surosree Ganguli,1 Peter DeLeeuw,2 Sanjaya K Satapathy3 1Division of Internal Medicine, University of Louisville, Louisville, KY 40202, USA; 2Division of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA; 3Division of Hepatology and Sandra Atlas Bass Center for...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ganguli S, DeLeeuw P, Satapathy SK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	nafld nash obesity cirrhosis treatment Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/acfb6ebad0b44dd59bdcc63f07870f85
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:acfb6ebad0b44dd59bdcc63f07870f85
record_format	dspace
spelling	oai:doaj.org-article:acfb6ebad0b44dd59bdcc63f07870f852021-12-02T05:15:54ZA Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis1179-1535https://doaj.org/article/acfb6ebad0b44dd59bdcc63f07870f852019-11-01T00:00:00Zhttps://www.dovepress.com/a-review-of-current-and-upcoming-treatment-modalities-in-non-alcoholic-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Surosree Ganguli,1 Peter DeLeeuw,2 Sanjaya K Satapathy3 1Division of Internal Medicine, University of Louisville, Louisville, KY 40202, USA; 2Division of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA; 3Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases, Northwell Health, Manhasset, NY 11030, USACorrespondence: Sanjaya K SatapathySandra Atlas Bass Center for Liver Diseases & Transplantation, Division of Hepatology, Department of Medicine, Northshore University Hospital/Northwell Health, 400 Community Drive, Manhasset, NY 11030, USATel +1 516 562 0510Fax +1 516 562 2688Email ssatapat@northwell.eduAbstract: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the West. Non-alcoholic steatohepatitis (NASH) is the progressive form of NAFLD and can lead to cirrhosis, hepatocellular carcinoma, and is associated with increased cardiovascular risks. Multiple components and risk factors are thought to be involved in the pathogenesis of NAFLD and NASH. Optimal therapy has not yet been found, but many advances have been made with the discovery of potential therapeutic options. In this paper, we aim to provide a comprehensive review of approved, studied, and upcoming treatment options for NAFLD and NASH. Non-pharmacologic therapy (lifestyle modifications and bariatric surgery) and pharmacologic therapy are both reviewed. Pharmacologic therapy target components thought to be involved in the pathogenesis of this disease process including insulin resistance, oxidative stress, inflammation, lipid metabolism, and fibrosis are reviewed in this paper. Results of the emerging treatment targets in phase 2 and 3 clinical trials are also included.Keywords: NAFLD, NASH, obesity, cirrhosis, treatmentGanguli SDeLeeuw PSatapathy SKDove Medical PressarticlenafldnashobesitycirrhosistreatmentDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 11, Pp 159-178 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	nafld nash obesity cirrhosis treatment Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	nafld nash obesity cirrhosis treatment Diseases of the digestive system. Gastroenterology RC799-869 Ganguli S DeLeeuw P Satapathy SK A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
description	Surosree Ganguli,1 Peter DeLeeuw,2 Sanjaya K Satapathy3 1Division of Internal Medicine, University of Louisville, Louisville, KY 40202, USA; 2Division of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA; 3Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases, Northwell Health, Manhasset, NY 11030, USACorrespondence: Sanjaya K SatapathySandra Atlas Bass Center for Liver Diseases & Transplantation, Division of Hepatology, Department of Medicine, Northshore University Hospital/Northwell Health, 400 Community Drive, Manhasset, NY 11030, USATel +1 516 562 0510Fax +1 516 562 2688Email ssatapat@northwell.eduAbstract: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the West. Non-alcoholic steatohepatitis (NASH) is the progressive form of NAFLD and can lead to cirrhosis, hepatocellular carcinoma, and is associated with increased cardiovascular risks. Multiple components and risk factors are thought to be involved in the pathogenesis of NAFLD and NASH. Optimal therapy has not yet been found, but many advances have been made with the discovery of potential therapeutic options. In this paper, we aim to provide a comprehensive review of approved, studied, and upcoming treatment options for NAFLD and NASH. Non-pharmacologic therapy (lifestyle modifications and bariatric surgery) and pharmacologic therapy are both reviewed. Pharmacologic therapy target components thought to be involved in the pathogenesis of this disease process including insulin resistance, oxidative stress, inflammation, lipid metabolism, and fibrosis are reviewed in this paper. Results of the emerging treatment targets in phase 2 and 3 clinical trials are also included.Keywords: NAFLD, NASH, obesity, cirrhosis, treatment
format	article
author	Ganguli S DeLeeuw P Satapathy SK
author_facet	Ganguli S DeLeeuw P Satapathy SK
author_sort	Ganguli S
title	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
title_short	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
title_full	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
title_fullStr	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
title_full_unstemmed	A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
title_sort	review of current and upcoming treatment modalities in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/acfb6ebad0b44dd59bdcc63f07870f85
work_keys_str_mv	AT gangulis areviewofcurrentandupcomingtreatmentmodalitiesinnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitis AT deleeuwp areviewofcurrentandupcomingtreatmentmodalitiesinnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitis AT satapathysk areviewofcurrentandupcomingtreatmentmodalitiesinnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitis AT gangulis reviewofcurrentandupcomingtreatmentmodalitiesinnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitis AT deleeuwp reviewofcurrentandupcomingtreatmentmodalitiesinnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitis AT satapathysk reviewofcurrentandupcomingtreatmentmodalitiesinnonalcoholicfattyliverdiseaseandnonalcoholicsteatohepatitis
_version_	1718400492469485568

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis

Ejemplares similares